Tolvaptan
Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00071331/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 3600 чел. во всех странах исследования.
- Центров в реестре: 24 в 4 городах. Список — ниже на странице.
- Плановая дата окончания (07.2006) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 27
Критерии включения
- Age greater than or equal to 18 years.
- Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to randomization. Chronic heart failure is defined as requiring treatment for a minimum of 30 days prior to hospitalization.
- The subject must have signs of extracellular volume expansion, defined as two or more of the following: a) jugular venous distention; b) pitting edema (>1+); or c) dyspnea.
- NYHA Class III or IV at the time of hospitalization.
- Left Ventricular Ejection Fraction < = 40% within one year.
Критерии невключения
- Women who will not adhere to the reproductive precautions as outlined in the Informed Consent form.
- Positive urine pregnancy test.
- Inability to provide written informed consent.
- Cardiac surgery within 60 days of potential study enrollment, excluding percutaneous coronary interventions.
- Planned revascularization procedures, electrophysiologic (EP) device implantation, cardiac mechanical support implantation, cardiac transplantation, or other cardiac surgery within 30 days following study enrollment.
- Subjects who are on cardiac mechanical support.
- History of bi-ventricular pacer placement within the last 60 days.
- Co-morbid condition with an expected survival less than six months.
- Subjects with acute ST segment elevation myocardial infarction at the time of hospitalization.
- History of sustained ventricular tachycardia or ventricular fibrillation within 30 days, unless in the presence of an automatic implantable cardioverter defibrillator.
- History of a cerebrovascular accident within the last 30 days.
- Hemodynamically significant uncorrected primary cardiac valvular disease.
- Hypertrophic cardiomyopathy (obstructive or non-obstructive).
- CHF due to uncorrected thyroid disease, active myocarditis or known amyloid cardiomyopathy.
- Subjects with progressive or episodic neurological disease such as multiple sclerosis or history of multiple strokes.
- History of primary significant liver disease or acute hepatic failure, as defined by the investigator.
- History of poorly controlled diabetes mellitus.
- Morbid obesity, defined as > 159 kg (or 350 lbs) or BMI > 40.
- Supine systolic arterial blood pressure < 90 mmHg.
- Serum creatinine > 3.5 mg/dL or > 309.4 mmol/L.
- Serum potassium > 5.5 mEq/L or > 5.5 mmol/L.
- Hemoglobin < 9 g/dL or < 90 g/L.
- History of hypersensitivity and/or idiosyncratic reaction to benzazepine derivatives (such as benazapril).
- History of drug or medication abuse within the past year, or current alcohol abuse.
- Inability to take oral medications.
- Participation in another clinical drug or device trial within the past 30 days.
- Previous participation in this or any other tolvaptan clinical trial.
Источник: ClinicalTrials.gov, NCT00071331 · запись обновлена в реестре 3 мая 2012.
Дизайн и результаты
Цель исследования
The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
Где проходит
24 центра в 4 городах- Cardiology Research Center
- Central Clinical Hospital of the presidentof the Russian Federation
- Institute of Physico-Chemical Medicine
- Medical Center of General Management
- Moscow Medical Academy
- Moscow Regional Research Clinical Institute n.a. Vishnevsky
- Moscow State University of Medicine and Dentistry
- Moscow State University of Medicine and Dentistry - City Hospital #11
- Moscow State University of Medicine and Dentistry - City Hospital #40
- Russian State Medical University
- ГБУЗ города Москвы «Госпиталь для ветеранов войн №3 ДЗМ»
- ГБУЗ города Москвы Городская клиническая больница имени С.П. Боткина ДЗМ
- ФГБУ «Главный военный клинический госпиталь имени академика Н.Н. Бурденко» Минобороны России
- Cardiology Research Institute of the Ministry of Health of the Russian Federation
- City Alexandrovsky Hospital, ICU Department
- City Hospital #31
- Federal State Budgetary Health Institution St. Petersburg Clinical Hospital of the Russian Academy of Sciences
- Military Medical Academy
- Saint-Petersburg I.I. Dzhanelidze Research Institute of Emergency Medicine
- St Petersburg Medical Academy of Postgraduate Education
- St. Petersburg State Medical Institution: Municipal Hospital of St. Elizabeth
- ФГБОУ ВО «Санкт-Петербургский государственный университет»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00071331 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.